| Literature DB >> 19386138 |
Anne Liljander1, Lisa Wiklund, Nicole Falk, Margaret Kweku, Andreas Mårtensson, Ingrid Felger, Anna Färnert.
Abstract
BACKGROUND: Genotyping of Plasmodium falciparum based on PCR amplification of the polymorphic genes encoding the merozoite surface proteins 1 and 2 (msp1 and msp2) is well established in the field of malaria research to determine the number and types of concurrent clones in an infection. Genotyping is regarded essential in anti-malarial drug trials to define treatment outcome, by distinguishing recrudescent parasites from new infections. Because of the limitations in specificity and resolution of gel electrophoresis used for fragment analysis in most genotyping assays it became necessary to improve the methodology. An alternative technique for fragment analysis is capillary electrophoresis (CE) performed using automated DNA sequencers. Here, one of the most widely-used protocols for genotyping of P. falciparum msp1 and msp2 has been adapted to the CE technique. The protocol and optimization process as well as the potentials and limitations of the technique in molecular epidemiology studies and anti-malarial drug trials are reported.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19386138 PMCID: PMC2680902 DOI: 10.1186/1475-2875-8-78
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Oligonucleotide primers for msp1 and msp2 genotyping and fluorescent modifications for the CE method
| Primer sequencesa | Fluorophore modificationb | |
| Segment-specific primers for block 2 of | ||
| In the primary reaction | ||
| 5'-CTAGAAGCTTTAGAAGATGCAGTATTG-3' | ||
| 5'-CTTAAATAGTATTCTAATTCAAGTGGATCA -3' | ||
| 5'-ATGAAGGTAATTAAAACATT GTCTATTATA-3' | ||
| 5'- CTTTGTTACCATCGGTACATTCTT-3' | ||
| Allelic type-specific primers for | ||
| K1 F | 5'- AAATGAAGAAGAAATTACTACAAAAGGTGC-3' | 7 bp-tail |
| K1 R | 5'- GCTTGCATCAGCTGGAGGGCTTGCACCAGA-3' | NED™ (yellow) |
| MAD 20 F | 5'- AAATGAAGGAACAAGTGGAACAGCTGTTAC -3' | 7 bp-tail |
| MAD 20 R | 5'- ATCTGAAGGATTTGTACGTCTTGAATTACC'-3' | PET® (red) |
| RO33 F | 5'- TAAAGGATGGAGCAAATACTCAAGTTGTTG-3' | 7 bp-tail |
| RO33 R | 5'- CATCTGAAGGATTTGCAGCACCTGGAGATC-3' | VIC® (green) |
| Allelic type-specific primers for | ||
| FC27 F | 5'- AATACTAAGAGTGTAGGTGCARATGCTCCA-3' | 7 bp-tail |
| FC27 R | 5'- TTTTAT TTG GTGCAT TGCCAGAAC TTG AAC-3' | 6-FAM™ (blue) |
| IC c F | 5'- AGAAGTATGGCAGAAAGTAAKCCTYCTACT-3' | 7 bp-tail |
| ICc R | 5'- GATTGTAATTCGGGGGATTCAGTTTGTTCG-3' | VIC® (green) |
a Primer sequences according to the original method [7,16]
b Modification of the primers used in the CE-based method
c Also referred to as 3D7 type
F = forward R = reverse
Figure 1Screenshot of electropherogram (GeneMapper. The red striped line indicates the cut-off at 300 relative fluorescent units (rfu). B) Companion peak, to the left of a true peak of an msp1 K1 allele from a single laboratory line. C) Stutter peaks in a sample with the K1 laboratory line amplified with msp2 FC27 primers. The y-axis depicts the rfu while fragment size (sz) in base pair and rfu height (ht) for individual alleles is depicted on the x-axis. The rfu scale on the y-axis has been adjusted to focus on the artifacts.
Genotyping of msp1 and msp2 in laboratory lines in different dilutions and mixtures using CE and gel electrophoresis
| K1 | MAD20 | RO33 | FC27 | IC | |||||||
| Lines | Densitya | CEb | gelc | CEb | gelc | CEb | gelc | CEb | gelc | CEb | gelc |
| F32 | 1000 | 0 | 0 | 192.99 | 205.50 | 0 | 0 | 0 | 0 | 524.09 | 539.10 |
| 100 | 0 | 0 | 193.01 | 207.06 | 0 | 0 | 0 | 0 | 524.05 | 539.12 | |
| 50 | 0 | 0 | 192.94 | 203.59 | 0 | 0 | 0 | 0 | 524.07 | 539.28 | |
| 10 | 0 | 0 | 193.02 | 201.20 | 0 | 0 | 0 | 0 | 524.25 | 519.80 | |
| 5 | 0 | 0 | 192.99 | 205.10 | 0 | 0 | 0 | 0 | 524.06 | 540.91 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| K1 | 1000 | 173.48 | 177.61 | 0 | 0 | 0 | 0 | 372.82 | 392.41 | 0 | 0 |
| 100 | 173.43 | 180.28 | 0 | 0 | 0 | 0 | 372.85 | 378.61 | 0 | 0 | |
| 50 | 173.30 | 179.85 | 0 | 0 | 0 | 0 | 372.87 | 381.90 | 0 | 0 | |
| 10 | 173.64 | 182.89 | 0 | 0 | 0 | 0 | 372.86 | 382.01 | 0 | 0 | |
| 5 | 173.56 | 182.51 | 0 | 0 | 0 | 0 | 372.85 | 395.98 | 0 | 0 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 7G8 | 1000 | 0 | 0 | 0 | 0 | 157.06 | 165.55 | 0 | 0 | 493.14 | 488.25 |
| 100 | 0 | 0 | 0 | 0 | 157.35 | 162.95 | 0 | 0 | 493.13 | 488.21 | |
| 50 | 0 | 0 | 0 | 0 | 157.23 | 167.94 | 0 | 0 | 493.16 | 472.87 | |
| 10 | 0 | 0 | 0 | 0 | 157.33 | 160.40 | 0 | 0 | 493.19 | 515.93 | |
| 5 | 0 | 0 | 0 | 0 | 157.19 | 165.92 | 0 | 0 | 0 | 508.05 | |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| F32/K1 | 1000/10 | 173.60 | 177.06 | 192.98 | 197.04 | 0 | 0 | 0 | 0 | 523.52 | 509.46 |
| 500/500 | 173.66 | 174.49 | 192.96 | 194.87 | 0 | 0 | 372.99 | 380.85 | 524.25 | 521.31 | |
| 10/1000 | 173.69 | 182.86 | 193.02 | 192.74 | 0 | 0 | 372.96 | 379.48 | 524.19 | 519.79 | |
| K1/7G8 | 1000/10 | 173.64 | 178.01 | 0 | 0 | 157.31 | 152.59 | 372.97 | 364.85 | 493.51 | 483.32 |
| 500/500 | 173.60 | 175.39 | 0 | 0 | 157.34 | 161.56 | 372.98 | 363.65 | 493.43 | 485.01 | |
| 10/1000 | 173.61 | 172.85 | 0 | 0 | 157.26 | 161.57 | 0 | 0 | 493.38 | 500.08 | |
| F32/7G8 | 1000/10 | 0 | 0 | 193.08 | 190.99 | 157.49 | 0 | 0 | 0 | 524.20/492.68 | 521.99/0 |
| 500/500 | 0 | 0 | 193.08 | 188.05 | 157.49 | 165.59 | 0 | 0 | 524.19/493.47 | 539.46/0 | |
| 10/1000 | 0 | 0 | 193.07 | 183.33 | 157.52 | 163.02 | 0 | 0 | 524.08/493.41 | 0/493.20 | |
a parasites/μl
b Fragment siz (bp) including 7 bp tail + A, determined by GeneMapper® soft ware after simplex PCR
c Fragment sizes (bp) determined by Quality One 4.4.1 analysis software
Figure 2Genotyping of .
Figure 3. MW: 100 base-pair DNA ladder.
Msp1 and msp2 genotyping by CE and gel electrophoresis of 240 microscopy P. falciparum-positive samples from asymptomatic children
| Capillary electrophoresis | Gel electrophoresis | |||||||||||||
| K1 | MAD20 | RO33 | total | FC27 | IC | total | K1 | MAD20 | RO33 | total | FC27 | IC | total | |
| PCR positive | 195 | 129 | 124 | 223 | 169 | 204 | 223 | 197 | 129 | 126 | 223 | 166 | 201 | 223 |
| Fragmentsa | 314 | 160 | 124 | 598 | 230 | 415 | 645 | 225 | 147 | 126 | 498 | 191 | 253 | 444 |
| Frequencyb | 33 | 14 | 1 | 48 | 20 | 76 | 96 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
| Meanc | 1.61 | 1.24 | 1.0 | 2.68 | 1.37 | 2.03 | 2.89 | 1.14 | 1.14 | 1.0 | 2.23 | 1.15 | 1.26 | 1.99 |
a Total number of detected msp1 and msp2 fragments
b number of different alleles detected in all samples, size bins of 3 bp
c Number of alleles/sample, excluding all parasite-negative samples
n.d. not determined
Stepwise genotyping of msp2 and msp1 in paired samples collected from children with uncomplicated P. falciparum malaria participating in an anti-malarial drug trial in Zanzibar.
| Outcome | Child (study ID) | Daya | FC27b | ICb | K1b | MAD20b | RO33b |
| Recrudescences | K152 | 0 | - | - | - | ||
| K152 | 21 | - | - | - | |||
| K97 | 0 | - | - | - | |||
| K97 | 21 | - | - | - | |||
| M107 | 0 | - | - | - | |||
| M107 | 21 | - | - | - | |||
| M131 | 0 | - | - | - | |||
| M131 | 21 | - | - | - | |||
| M152 | 0 | - | - | - | |||
| M152 | 21 | - | - | - | |||
| New infections | K108 | 0 | 515.38 | - | - | 157.53 | |
| K108 | 42 | - | 246.43 | - | - | ||
| K149 | 0 | 452.49 | 182.77 | 201.89 | - | ||
| K149 | 28 | 580.85 | 300.79 | 210.91 | - | ||
| M161 | 0 | 531.02 | 138.73 | 210.81 | - | ||
| M161 | 21 | 622.87 | 182.72 | 192.88 | 157.62 | ||
| M164 | 0 | 632.64 | 228.45 | - | - | ||
| M164 | 28 | 560.93 | 255.70 | - | 157.53 | ||
| M165 | 0 | 335.91 | 464.33 | 210.07 | 210.81 | 157.61 | |
| M165 | 28 | - | 228.28 | - | - | ||
| M173 | 0 | 531.85 | 246.31 | 220.0 | - | ||
| M173 | 42 | 499.35 | 201.10 | 246.88 | - | ||
Outcome classified by msp2 followed by msp1 genotyping to confirm recrudescence (bold) or new infection.
a Paired blood samples collected before initiation of anti-malarial treatment (day 0) and at day of recurrent parasitaemia (days 21–42)
b Fragment sizes in bp
- negative result